Сравнение эффективности оригинальной и генерической формы клопидогреля у больных с ИБС

Background. To evaluate the antiaggregation activity and clinical tolerability of Areplex (75 mg, ADAMED, Poland) compared to Plavix (75 mg, Sanofi-Winthrop Industrie, France) in CAD patients. Materials and methods. A blinded, randomized, two-parallel-group study included 40 patients with stable angina (FC I-IV). Platelet aggregation was assessed using the AP 2110 analyzer (SOLAR) with ADP (5 µmol/L) and arachidonic acid (0.5 mg/mL) inducers after a 300 mg loading dose. Results. At 24 hours post-dose, both groups showed significant reductions in aggregation degree and rate (p<0.05), with no intergroup differences (p>0.05). Safety profiles were comparable, with no adverse events reported. Conclusion. Areplex demonstrated bioequivalence to Plavix, with good tolerability, supporting its use as an effective antiplatelet agent in CAD patients.